Actively Recruiting

Phase Not Applicable
Age: 18Years - 50Years
All Genders
NCT07274917

Stereotactic Radiotherapy Treatment for Treatment-resistant Depression

Led by Capital Medical University · Updated on 2026-04-27

9

Participants Needed

1

Research Sites

122 weeks

Total Duration

On this page

Sponsors

C

Capital Medical University

Lead Sponsor

C

Chinese PLA General Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression

CONDITIONS

Official Title

Stereotactic Radiotherapy Treatment for Treatment-resistant Depression

Who Can Participate

Age: 18Years - 50Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged 18 to 50 years, any gender
  • Diagnosed with recurrent major depressive disorder without psychotic features according to DSM-5
  • Documented treatment-resistant depression with less than 50% improvement after at least two adequate antidepressant treatments during the current episode
  • Hamilton Depression Rating Scale 17-item (HAMD-17) score of 20 or higher at screening and baseline
  • Willing to maintain current antidepressant therapy unchanged during the study
  • Able and willing to provide informed consent and follow study procedures
Not Eligible

You will not qualify if you...

  • Diagnosis or history of other DSM-5 mental disorders such as bipolar disorder, schizophrenia, obsessive-compulsive disorder, substance use disorders, or personality disorders
  • Significant unstable or severe medical conditions including cardiovascular, respiratory, digestive, endocrine, urinary, hematological, nervous system diseases, or tumors
  • Severe neurological diseases or impairments including increased intracranial pressure, brain lesions, stroke, epilepsy (except ECT-induced), cerebral aneurysm, Parkinson's, Huntington's, multiple sclerosis, or severe head trauma
  • High suicide risk based on recent suicidal ideation or behavior assessments
  • Participation in other neuromodulation therapies or clinical trials recently
  • Non-response to systematic MECT treatment
  • History of psychosurgical procedures or prior radiotherapy, chemotherapy, immunotherapy, or radiation/toxic exposure
  • Contraindications to MRI such as metallic implants, pacemakers, cochlear implants, or claustrophobia
  • Pregnant or lactating women or unwillingness to use effective contraception
  • Body weight over 150 kg
  • Any other condition deemed unsuitable by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Anding Hospital, Capital Medical University

Beijing, China

Actively Recruiting

Loading map...

Research Team

A

Aihong Yu, Prof., Medical Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here